The United States has completed an investigation into the possible neurological effect in two vaccine trial participants.
In the United States, federal health authorities have authorized British-Swedish pharmaceutical company AstraZeneca to resume trials of a coronavirus vaccine. This is reported by the Wall Street Journal on Friday, October 23, citing sources and documents at its disposal.
The FDA has completed an investigation into possible neurological effects in two vaccine trial participants.
According to the interlocutors of the publication, the regulator has not established a connection between the introduction of the vaccine and the onset of symptoms, but it cannot exclude it.
We will remind that earlier Trump announced the emergence of a vaccine against COVID-19 as soon as possible. As soon as the vaccine against the new type of coronavirus infection is ready, the United States plans to distribute about 100 million doses.